Korsana Biosciences (KRSA) vs uniQure N.V. (QURE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Korsana Biosciences (KRSA) has outperformed uniQure N.V. (QURE) over the past year, gaining 96.2% versus a loss of 64.5%. Over five years, QURE leads with a -25.0% price change compared with -91.0% for KRSA. uniQure N.V. is the larger company by market cap ($1.57 billion vs $1.54 billion), about 1.0 times the size, while Korsana Biosciences is growing revenue faster (+3.7% vs -40.6%).
Korsana Biosciences converts more of its revenue into profit, with a net margin of -170.1% versus -1236.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRSA | QURE |
|---|---|---|
| Share price | $33.92 | $22.59 |
| Market cap | $1.54B | $1.57B |
| 1-day change | +1.22% | +0.22% |
| YTD return | +281.55% | -5.60% |
| 1-year return | +96.18% | -64.51% |
| 5-year return | -90.99% | -25.02% |
| EPS (TTM) | $-7.07 | $-4.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.07M | $16.10M |
| Revenue growth (YoY) | +3.70% | -40.64% |
| Net income (latest FY) | $-3.53M | $-198.97M |
| Gross margin | — | 89.53% |
| Operating margin | -239.78% | -1151.38% |
| Net margin | -170.11% | -1236.00% |
| 52-week high | $59.36 | $71.50 |
| 52-week low | $7.19 | $8.73 |
| Distance from 52-week high | -42.86% | -68.41% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +29.72% | +175.92% |
| Average volume | 32.06K | 1.97M |
| Shares outstanding | 45.54M | 69.37M |
| Employees | 19 | 221 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRSA has outperformed QURE by 160.7 percentage points over the past year.
- Korsana Biosciences is more profitable, keeping -170.1 cents of every revenue dollar as net income versus -1236.0 cents for uniQure N.V..
- Korsana Biosciences grew revenue faster in its latest fiscal year (+3.70% vs -40.64%).
About Korsana Biosciences
KRSA stock →Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About uniQure N.V.
QURE stock →uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 221 employees
KRSA vs QURE FAQ
Which is bigger, Korsana Biosciences or uniQure N.V.?
uniQure N.V. (QURE) is larger, with a market capitalization of $1.57B compared with $1.54B for Korsana Biosciences (KRSA).
Which stock has performed better over the past year, KRSA or QURE?
KRSA returned +96.18% over the past 12 months, compared with -64.51% for QURE (price return, excluding dividends). Past performance does not predict future results.
Are Korsana Biosciences and uniQure N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.